Visualization firms invest in TeraRecon

Article

Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal

Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal in March; Pentax signed its agreement in May. Both agreements were announced earlier this month. Fujifilm paid $4.95 million to acquire 300,000 shares of newly issued series G preferred stock, representing a 1.92% equity stake in TeraRecon. Under the terms of the alliance, TeraRecon will apply its signal and image processing technologies to new product and technology development at Fuji. Pentax paid $5.67 million to acquire 341,000 shares of newly issued series G preferred stock, representing 2.18% of issued equity. In return, Pentax has the right to include TeraRecon technology in products such as those involving optical endoscopic imaging and consumer electronics digital camera applications.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.